BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 30481785)

  • 1. ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2.
    Cui Y; Qin L; Tian D; Wang T; Fan L; Zhang P; Wang Z
    Chemotherapy; 2018; 63(5):262-271. PubMed ID: 30481785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gambogic Acid Inhibits Melanoma through Regulation of miR-199a-3p/ZEB1 Signalling.
    Liang L; Zhang Z; Qin X; Gao Y; Zhao P; Liu J; Zeng W
    Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):692-703. PubMed ID: 29959879
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Chi C; Mao M; Shen Z; Chen Y; Chen J; Hou W
    Hum Gene Ther; 2018 Dec; 29(12):1438-1448. PubMed ID: 29896986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRIAP1 Inhibition Activates the Cytochrome c/Apaf-1/Caspase-9 Signaling Pathway to Enhance Human Ovarian Cancer Sensitivity to Cisplatin.
    Zhang TM
    Chemotherapy; 2019; 64(3):119-128. PubMed ID: 31661694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
    Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
    Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
    Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
    Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCAT-1 contributes to cisplatin resistance in gastric cancer through miR-128/ZEB1 axis.
    Guo Y; Yue P; Wang Y; Chen G; Li Y
    Biomed Pharmacother; 2019 Oct; 118():109255. PubMed ID: 31352238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion.
    Wang H; Luo Y; Qiao T; Wu Z; Huang Z
    J Ovarian Res; 2018 Nov; 11(1):93. PubMed ID: 30454003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
    He J; Yu JJ; Xu Q; Wang L; Zheng JZ; Liu LZ; Jiang BH
    Autophagy; 2015; 11(2):373-84. PubMed ID: 25650716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of down-regulated transcriptional repressor ZEB1 on the epithelial-mesenchymal transition of ovarian cancer cells.
    Chen D; Wang J; Zhang Y; Chen J; Yang C; Cao W; Zhang H; Liu Y; Dou J
    Int J Gynecol Cancer; 2013 Oct; 23(8):1357-66. PubMed ID: 24257549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of survivin contributes to antitumor activity in cisplatin-resistant ovarian cancer cells.
    Jiang L; Luo RY; Yang J; Cheng YX
    Mol Med Rep; 2013 Feb; 7(2):425-30. PubMed ID: 23229441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of Fas in epithelial ovarian cancer reverses the development of resistance to cisplatin.
    Yang F; Long W; Xuechuan H; Xueqin L; Hongyun M; Yonghui D
    BMB Rep; 2015 Jan; 48(1):30-5. PubMed ID: 24755555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B X-interacting protein promotes cisplatin resistance and regulates CD147 via Sp1 in ovarian cancer.
    Zou W; Ma X; Yang H; Hua W; Chen B; Cai G
    Exp Biol Med (Maywood); 2017 Mar; 242(5):497-504. PubMed ID: 28056551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway.
    Yang X; Zhang Q; Yang X; Zhao M; Yang T; Yao A; Tian X
    Biochem Biophys Res Commun; 2019 Apr; 511(4):719-724. PubMed ID: 30827507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.
    Hui C; Lan Z; Yue-li L; Li-lin H; Li-lin H
    Reprod Sci; 2015 Dec; 22(12):1618-26. PubMed ID: 26079730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of microRNA-1271 on ovarian cancer via inhibition of epithelial-mesenchymal transition and cisplatin resistance.
    Chen Y; Wang L; Zhou J
    J Obstet Gynaecol Res; 2019 Nov; 45(11):2243-2254. PubMed ID: 31411791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZEB1 promotes prostate cancer proliferation and invasion through ERK1/2 signaling pathway.
    Song XF; Chang H; Liang Q; Guo ZF; Wu JW
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4032-4038. PubMed ID: 29028100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.